Item request has been placed!
×
Item request cannot be made.
×
![loading](/sites/all/modules/hf_eds/images/loading.gif)
Processing Request
HTR2B as a novel biomarker of chronic obstructive pulmonary disease with lung squamous cell carcinoma.
Item request has been placed!
×
Item request cannot be made.
×
![loading](/sites/all/modules/hf_eds/images/loading.gif)
Processing Request
- معلومة اضافية
- المصدر:
Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE
- بيانات النشر:
Original Publication: London : Nature Publishing Group, copyright 2011-
- الموضوع:
Pulmonary Disease, Chronic Obstructive*/
genetics ;
Pulmonary Disease, Chronic Obstructive*/
metabolism ;
Lung Neoplasms*/
genetics ;
Lung Neoplasms*/
pathology ;
Lung Neoplasms*/
metabolism ;
Biomarkers, Tumor*/
genetics ;
Biomarkers, Tumor*/
metabolism ;
Carcinoma, Squamous Cell*/
genetics ;
Carcinoma, Squamous Cell*/
pathology ;
Carcinoma, Squamous Cell*/
metabolism ;
Epithelial-Mesenchymal Transition*/
genetics;
Humans ;
Receptor, Serotonin, 5-HT2B/
genetics ;
Receptor, Serotonin, 5-HT2B/
metabolism ;
Gene Expression Regulation, Neoplastic ;
Cell Proliferation/
genetics ;
Cell Line, Tumor - نبذة مختصرة :
Chronic obstructive pulmonary disease (COPD) is often associated with lung squamous cell carcinoma (LUSC), which has the same etiology (smoking, inflammation, oxidative stress, microenvironmental changes, and genetics). Smoking, inflammation, and airway remodeling are the most important and classical mechanisms of COPD comorbidity in LUSC patients. Cancer can occur during repeated airway damage and repair (airway remodeling). Changes in the inflammatory and immune microenvironments, which can cause malignant transformation of some cells, are currently being revealed in both LUSC and COPD patients. We obtained the GSE76925 dataset from the Gene Expression Omnibus database. Screening for possible COPD biomarkers was performed using the LASSO regression model and a random forest classifier. The compositional patterns of the immune cell fraction in COPD patients were determined using CIBERSORT. HTR2B expression was analyzed using validation datasets (GSE47460, GSE106986, and GSE1650). HTR2B expression in COPD cell models was determined via real-time quantitative PCR. Epithelial-mesenchymal transition (EMT) marker expression levels were determined after knocking down or overexpressing HTR2B. HTR2B function and mechanism in LUSC were analyzed with the Kaplan‒Meier plotter database. HTR2B expression was inhibited to detect changes in LUSC cell proliferation. A total of 1082 differentially expressed genes (DEGs) were identified in the GSE76925 dataset (371 genes were significantly upregulated, and 711 genes were significantly downregulated). Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis indicated that the DEGs were mainly enriched in the p53 signaling and β-alanine metabolism pathways. Gene Ontology enrichment analysis indicated that the DEGs were largely related to transcription initiation from the RNA polymerase I promoter and to the regulation of mononuclear cell proliferation. The LASSO regression model and random forest classifier results revealed that HTR2B, DPYS, FRY, and CD19 were key COPD genes. Immune cell infiltration analysis indicated that these genes were closely associated with immune cells. Analysis of the validation sets suggested that HTR2B was upregulated in COPD patients. HTR2B was significantly upregulated in COPD cell models, and its upregulation was associated with increased EMT marker expression. Compared with that in bronchial epithelial cells, HTR2B expression was upregulated in LUSC cells, and inhibiting HTR2B expression led to the inhibition of LUSC cell proliferation. In conclusions, HTR2B might be a new biomarker and therapeutic target in COPD patients with LUSC.
(© 2024. The Author(s).)
- References:
Explor Target Antitumor Ther. 2023;4(5):850-895. (PMID: 37970206)
Eur Respir Rev. 2023 Apr 19;32(168):. (PMID: 37076177)
Heliyon. 2024 Apr 17;10(8):e29840. (PMID: 38681577)
Cancers (Basel). 2024 Mar 22;16(7):. (PMID: 38610929)
Ann Oncol. 2021 Sep;32(9):1101-1110. (PMID: 34089836)
Front Cell Dev Biol. 2024 Feb 05;12:1339251. (PMID: 38374894)
Nat Rev Cancer. 2023 Jul;23(7):491-505. (PMID: 37277485)
Int J Mol Sci. 2023 Feb 02;24(3):. (PMID: 36769181)
Am J Physiol Lung Cell Mol Physiol. 2020 Nov 1;319(5):L879-L883. (PMID: 32964724)
J Thorac Oncol. 2023 Oct;18(10):1277-1289. (PMID: 37277094)
Chest. 2024 May;165(5):e158-e159. (PMID: 38724158)
Nat Rev Genet. 2024 Mar 6;:. (PMID: 38448562)
Lancet Respir Med. 2024 Jan;12(1):15-16. (PMID: 38061380)
Chest. 2024 May;165(5):1027-1028. (PMID: 38724136)
Int J Chron Obstruct Pulmon Dis. 2022 Oct 17;17:2603-2621. (PMID: 36274992)
Cancer Res. 2023 Dec 1;83(23):3868-3885. (PMID: 38037454)
Minerva Med. 2024 Feb;115(1):23-31. (PMID: 37021471)
Sci China Life Sci. 2024 May;67(5):940-957. (PMID: 38212458)
Chest. 2023 Nov;164(5):1315-1324. (PMID: 37209772)
Mol Cancer. 2023 Feb 21;22(1):40. (PMID: 36810079)
Cells. 2022 Aug 14;11(16):. (PMID: 36010598)
Am J Cancer Res. 2024 Apr 15;14(4):1561-1576. (PMID: 38726259)
Oncogene. 2021 Apr;40(16):2817-2829. (PMID: 33707749)
Nucleic Acids Res. 2023 Jan 6;51(D1):D587-D592. (PMID: 36300620)
Biomed Res Int. 2019 Jun 24;2019:2025636. (PMID: 31341890)
Ageing Res Rev. 2024 Jun;97:102315. (PMID: 38679394)
Front Oncol. 2023 Feb 01;13:1124167. (PMID: 37077826)
Biomed Pharmacother. 2023 Dec 31;169:115891. (PMID: 37979378)
Int J Chron Obstruct Pulmon Dis. 2024 Jan 05;19:33-50. (PMID: 38197032)
Cancers (Basel). 2023 Apr 13;15(8):. (PMID: 37190212)
BMC Cancer. 2023 Jun 5;23(1):507. (PMID: 37277751)
Respir Res. 2022 Sep 20;23(1):260. (PMID: 36127695)
Int Immunopharmacol. 2020 Apr;81:106036. (PMID: 31787571)
Front Med (Lausanne). 2023 Apr 27;10:1118863. (PMID: 37181380)
Int J Chron Obstruct Pulmon Dis. 2024 Feb 29;19:567-578. (PMID: 38476124)
Mol Cancer Res. 2024 Jun 4;22(6):538-554. (PMID: 38381131)
Cancer. 2024 Apr 15;130(8):1330-1348. (PMID: 38279776)
Am J Respir Crit Care Med. 2024 Jan 18;:. (PMID: 38236192)
Int J Mol Sci. 2024 Mar 09;25(6):. (PMID: 38542151)
J Immunol Res. 2022 Jun 22;2022:1429213. (PMID: 35785027)
Tumour Biol. 2024;46(s1):S283-S295. (PMID: 37270828)
- Grant Information:
LHGJ20230169 Medical Science and Technology Research Project of Henan Province
- Contributed Indexing:
Keywords: Biomarker; COPD; EMT; LUSC; Machine learning
- الرقم المعرف:
0 (Biomarkers, Tumor)
0 (Receptor, Serotonin, 5-HT2B)
- الموضوع:
Date Created: 20240608 Date Completed: 20240608 Latest Revision: 20240611
- الموضوع:
20240611
- الرقم المعرف:
PMC11162446
- الرقم المعرف:
10.1038/s41598-024-63896-x
- الرقم المعرف:
38851806
No Comments.